131 related articles for article (PubMed ID: 10966495)
1. Endothelin A receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals.
Amann K; Münter K; Wessels S; Wagner J; Balajew V; Hergenröder S; Mall G; Ritz E
J Am Soc Nephrol; 2000 Sep; 11(9):1702-1711. PubMed ID: 10966495
[TBL] [Abstract][Full Text] [Related]
2. ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and fibrosis of the heart in experimental diabetes.
Gross ML; Heiss N; Weckbach M; Hansen A; El-Shakmak A; Szabo A; Münter K; Ritz E; Amann K
Diabetologia; 2004 Feb; 47(2):316-24. PubMed ID: 14727024
[TBL] [Abstract][Full Text] [Related]
3. Endothelin receptor antagonists influence cardiovascular morphology in uremic rats.
Nabokov AV; Amann K; Wessels S; Münter K; Wagner J; Ritz E
Kidney Int; 1999 Feb; 55(2):512-9. PubMed ID: 9987075
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival and hemodynamics after endothelin-a receptor antagonism and angiotensin-converting enzyme inhibition in rats with chronic heart failure: monotherapy versus combination therapy.
Mulder P; Boujedaini H; Richard V; Henry JP; Renet S; Münter K; Thuillez C
Circulation; 2002 Aug; 106(9):1159-64. PubMed ID: 12196345
[TBL] [Abstract][Full Text] [Related]
5. Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker.
Gross ML; Ritz E; Schoof A; Helmke B; Parkman A; Tulp O; Münter K; Amann K
Lab Invest; 2003 Sep; 83(9):1267-77. PubMed ID: 13679434
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibition and endothelin antagonism for endothelial dysfunction in heart failure: mono-or combination therapy.
Bauersachs J; Fraccarollo D; Schäfer A; Ertl G
J Cardiovasc Pharmacol; 2002 Oct; 40(4):594-600. PubMed ID: 12352322
[TBL] [Abstract][Full Text] [Related]
7. Remodeling of resistance arteries in renal failure: effect of endothelin receptor blockade.
Amann K; Mil Tenberger-Mil Tenyi G; Simonoviciene A; Koch A; Orth S; Ritz E
J Am Soc Nephrol; 2001 Oct; 12(10):2040-2050. PubMed ID: 11562402
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model.
Dhein S; Hochreuther S; Aus Dem Spring C; Bollig K; Hufnagel C; Raschack M
J Pharmacol Exp Ther; 2000 May; 293(2):351-9. PubMed ID: 10773002
[TBL] [Abstract][Full Text] [Related]
9. Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats.
Amann K; Gassmann P; Buzello M; Orth SR; Törnig J; Gross ML; Magener A; Mall G; Ritz E
Kidney Int; 2000 Jul; 58(1):153-61. PubMed ID: 10886560
[TBL] [Abstract][Full Text] [Related]
10. Trandolapril and endothelin antagonist LU-135252 in the treatment of the fructose-induced hypertensive, hyperinsulinemic, hypertriglyceridemic rat.
Ezra-Nimni O; Ezra D; Peleg E; Munter K; Rosenthal T
Am J Hypertens; 2003 Apr; 16(4):324-8. PubMed ID: 12670751
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined endothelin and angiotensin II antagonism on growth factor-induced proliferation of vascular smooth muscle cells isolated from uremic rats.
Wolf SC; Sauter G; Risler T; Brehm BR
Ren Fail; 2005; 27(4):465-74. PubMed ID: 16060137
[TBL] [Abstract][Full Text] [Related]
12. Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats.
Brochu E; Lacasse S; Moreau C; Lebel M; Kingma I; Grose JH; Larivière R
Nephrol Dial Transplant; 1999 Aug; 14(8):1881-8. PubMed ID: 10462266
[TBL] [Abstract][Full Text] [Related]
13. Myocyte/capillary mismatch in the heart of uremic patients.
Amann K; Breitbach M; Ritz E; Mall G
J Am Soc Nephrol; 1998 Jun; 9(6):1018-22. PubMed ID: 9621284
[TBL] [Abstract][Full Text] [Related]
14. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
Gross ML; El-Shakmak A; Szábó A; Koch A; Kuhlmann A; Münter K; Ritz E; Amann K
Diabetologia; 2003 Jun; 46(6):856-68. PubMed ID: 12802493
[TBL] [Abstract][Full Text] [Related]
15. Combination treatment with an ET(A)-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models.
Orth SR; Odoni G; Karkoszka H; Ogata H; Viedt C; Amann K; Ferrari P; Ritz E
Nephrol Dial Transplant; 2003 Jan; 18(1):62-9. PubMed ID: 12480961
[TBL] [Abstract][Full Text] [Related]
16. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation.
Nabokov A; Amann K; Wagner J; Gehlen F; Münter K; Ritz E
Nephrol Dial Transplant; 1996 Mar; 11(3):514-20. PubMed ID: 8671823
[TBL] [Abstract][Full Text] [Related]
17. Effect of endothelin blockade on early cardiovascular remodeling in the one-clip-two-kidney hypertension of the rat.
Saam T; Ehmke H; Haas C; Ritz E; Amann K
Kidney Blood Press Res; 2003; 26(5-6):325-32. PubMed ID: 14610336
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure.
Brochu E; Lacasse S; Larivière R; Kingma I; Grose JH; Lebel M
J Am Soc Nephrol; 1999 Jul; 10(7):1440-6. PubMed ID: 10405199
[TBL] [Abstract][Full Text] [Related]
19. Endothelin-receptor antagonists in uremic cardiomyopathy.
Wolf SC; Gaschler F; Brehm S; Klaussner M; Amann K; Risler T; Brehm BR
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S348-50. PubMed ID: 11078417
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage.
Amann K; Simonaviciene A; Medwedewa T; Koch A; Orth S; Gross ML; Haas C; Kuhlmann A; Linz W; Schölkens B; Ritz E
J Am Soc Nephrol; 2001 Dec; 12(12):2572-2584. PubMed ID: 11729225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
